My research revolves around tumor immunology and immunotherapy, with a special emphasis on exploring pathophysiological mechanisms driving immune tolerance to prostate tumor antigens and pre-clinically implementing novel cancer immunotherapy platforms. I am especially interested in the concept of combinatorial immunotherapy, which tests the translation potential of new breakthroughs in immune tolerance into efficient immunotherapeutic strategies in conjunction with cancer vaccines. This encompasses accurate targeting of tumors by the immune system through identification of highly specific tumor antigens and finding new ways to interfere with inhibitory mechanisms that compromise immune surveillance in cancer. Additionally, I am actively involved in several ongoing collaborative efforts with investigators within and outside the Harvard Medical School system. Examples include targeting NKT for cancer immunotherapy, manipulation of T cell and DC metabolome to modulate anti-tumor immunity, and identification of novel, putative tumor-specific markers that could serve as immunotherapy targets. Using the studies described above as a foundation, I envision my program expanding into other aspects of tumor immunology as a method of advancing our knowledge of tumor-immune interaction and identifying strategies to harness the new findings towards novel, more effective immunotherapies.